Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biological Specimen Banks | 4 | 2022 | 63 | 1.010 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2025 | 174 | 0.810 |
Why?
|
| Tetralogy of Fallot | 2 | 2025 | 181 | 0.810 |
Why?
|
| Stroke Volume | 1 | 2025 | 534 | 0.730 |
Why?
|
| Retinoblastoma | 3 | 2012 | 86 | 0.680 |
Why?
|
| Ventricular Function, Left | 1 | 2025 | 542 | 0.680 |
Why?
|
| Echocardiography | 1 | 2025 | 1137 | 0.590 |
Why?
|
| Biomedical Research | 3 | 2020 | 561 | 0.550 |
Why?
|
| Retinal Neoplasms | 2 | 2012 | 72 | 0.430 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 87 | 0.420 |
Why?
|
| Heart Septal Defects | 2 | 2025 | 45 | 0.390 |
Why?
|
| Picornaviridae | 2 | 2013 | 19 | 0.370 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 84 | 0.360 |
Why?
|
| Antigens, CD | 1 | 2012 | 413 | 0.320 |
Why?
|
| Glycoproteins | 1 | 2012 | 346 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 605 | 0.290 |
Why?
|
| Peptides | 1 | 2012 | 711 | 0.290 |
Why?
|
| Retina | 1 | 2012 | 451 | 0.290 |
Why?
|
| Mitral Valve Stenosis | 1 | 2025 | 34 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 214 | 0.220 |
Why?
|
| Genetic Therapy | 1 | 2007 | 719 | 0.190 |
Why?
|
| Public Opinion | 1 | 2022 | 63 | 0.180 |
Why?
|
| Reoperation | 1 | 2025 | 848 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 1842 | 0.170 |
Why?
|
| Receptor, Notch4 | 1 | 2020 | 5 | 0.170 |
Why?
|
| Bacillus | 1 | 2000 | 37 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 107 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2016 | 772 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 273 | 0.150 |
Why?
|
| Research Personnel | 1 | 2020 | 140 | 0.150 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 360 | 0.150 |
Why?
|
| Progesterone | 1 | 2000 | 441 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 403 | 0.140 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2022 | 276 | 0.130 |
Why?
|
| Down Syndrome | 1 | 2020 | 234 | 0.130 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1909 | 0.130 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 1353 | 0.130 |
Why?
|
| Child | 6 | 2025 | 26220 | 0.120 |
Why?
|
| Proteomics | 1 | 2020 | 607 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2025 | 1176 | 0.120 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 51 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 704 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Quality Control | 1 | 2016 | 115 | 0.120 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 140 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 145 | 0.110 |
Why?
|
| Infant | 3 | 2025 | 13332 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2016 | 310 | 0.110 |
Why?
|
| Humans | 20 | 2025 | 130980 | 0.110 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 675 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 972 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3133 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2562 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 1623 | 0.090 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 37 | 0.090 |
Why?
|
| AC133 Antigen | 1 | 2012 | 36 | 0.090 |
Why?
|
| Phenotype | 1 | 2022 | 4484 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 75 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2025 | 15018 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 4683 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2012 | 332 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2012 | 238 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 772 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 152 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 713 | 0.080 |
Why?
|
| Mice | 6 | 2013 | 18287 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 569 | 0.070 |
Why?
|
| Glioma | 1 | 2013 | 522 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 334 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 733 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 85 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2345 | 0.060 |
Why?
|
| Hyaluronan Receptors | 1 | 2006 | 64 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 390 | 0.060 |
Why?
|
| Female | 8 | 2025 | 70723 | 0.060 |
Why?
|
| Cystadenoma, Serous | 1 | 2005 | 16 | 0.060 |
Why?
|
| Azetidines | 1 | 2006 | 63 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 279 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 108 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 57 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 634 | 0.060 |
Why?
|
| Male | 4 | 2025 | 64783 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 329 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 707 | 0.060 |
Why?
|
| Animals | 6 | 2013 | 34025 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3417 | 0.050 |
Why?
|
| Phyllodes Tumor | 1 | 2004 | 9 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2004 | 17 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 29 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 582 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 61 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 23 | 0.050 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2003 | 2 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 41 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2003 | 65 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12957 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 357 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 56 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 104 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2022 | 11 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2022 | 18 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 170 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 239 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 452 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 2000 | 43 | 0.040 |
Why?
|
| Androstenedione | 1 | 2000 | 15 | 0.040 |
Why?
|
| Biotransformation | 1 | 2000 | 54 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 586 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 202 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 164 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 335 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2000 | 315 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 372 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 327 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 232 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5100 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 1005 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 360 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 734 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 359 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 990 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 150 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2022 | 857 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1282 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2022 | 683 | 0.030 |
Why?
|
| Glucose | 1 | 2000 | 853 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2212 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3717 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8568 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 802 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 397 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 6231 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 234 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 188 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 23 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 2014 | 149 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1053 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 752 | 0.020 |
Why?
|
| Troponin T | 1 | 2014 | 255 | 0.020 |
Why?
|
| Adult | 4 | 2025 | 31296 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2648 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 771 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 10016 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 257 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 11022 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2123 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 234 | 0.020 |
Why?
|
| Adolescent | 2 | 2025 | 20817 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2611 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4675 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1515 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1014 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1216 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1923 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2849 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 17764 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2006 | 94 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2145 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 111 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 182 | 0.010 |
Why?
|
| Mastectomy, Simple | 1 | 2004 | 1 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11852 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 567 | 0.010 |
Why?
|
| Omentum | 1 | 2004 | 39 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1852 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2003 | 50 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 92 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1952 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 137 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 902 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2004 | 68 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3731 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 231 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2574 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 628 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 806 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1317 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 972 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2939 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 4716 | 0.010 |
Why?
|
| Middle Aged | 2 | 2005 | 28555 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 6148 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 7501 | 0.010 |
Why?
|